Torres Irene Vinagre, Donlo Ignacio Conget
Unidad de Diabetes, Servicio de Endocrinología y Nutrición, Hospital Clínic i Universitari de Barcelona, IDIBAPS, Barcelona, España.
Unidad de Diabetes, Servicio de Endocrinología y Nutrición, Hospital Clínic i Universitari de Barcelona, IDIBAPS, Barcelona, España.
Med Clin (Barc). 2013 Sep;141 Suppl 2:3-6. doi: 10.1016/S0025-7753(13)70056-3.
Type 2 diabetes mellitus (DM2) is a highly prevalent chronic disease with major social and healthcare repercussions due to the development of acute and chronic complications. The care of patients with DM2 represents between 6.3% and 7.4% of the budget of the Spanish national health service and is mainly centered on hospital admissions and hypoglycemic agents, leading to an annual expenditure of 1.290 € to 1.476 € per patient. The attainment of glycemic targets remains complex and inadequate, despite new drugs for the treatment of DM2, the available scientific evidence, and national and international guidelines. The main causes proposed for failure to achieve these targets in DM2 are clinical inertia (found in 40% of physicians in Spain treating patients with HbA1c > 7%), poor treatment adherence, the problems inherent to the health system, and the natural history of the disease.
2型糖尿病（DM2）是一种高度流行的慢性病，因其急性和慢性并发症的发生而产生重大的社会和医疗影响。DM2患者的护理费用占西班牙国家卫生服务预算的6.3%至7.4%，主要集中在住院治疗和降糖药物上，导致每位患者每年的支出为1290欧元至1476欧元。尽管有治疗DM2的新药、现有的科学证据以及国家和国际指南，但实现血糖目标仍然复杂且不理想。DM2未能实现这些目标的主要原因包括临床惰性（在西班牙40%治疗糖化血红蛋白>7%患者的医生中存在）、治疗依从性差、卫生系统固有的问题以及疾病的自然史。
